Resources – Multiple Myeloma

Presentations and videos

Minimal residual disease in Myeloma Session 1

Minimal residual disease in Myeloma Session 2

Improving Survival in Multiple Myeloma

What’s new in Myeloma Treatment: a New Zealand Perspective

CAR T-cell Therapy: a New Frontier in Blood Cancer Treatment

Four Decades of Myeloma – Ken Romeril

Research and articles

August 15, 2019

Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data

Bortezomib in combination with cyclophosphamide and dexamethasone (CyBorD, is a well-established frontline chemotherapy regimen for patients with multiple myeloma, but prospective data on elderly non-transplant eligible patients is limited. A...

July 22, 2019

The VCAT study

Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study Development...

July 17, 2019

Lenalidomide-related Progressive Multifocal Leukoencephalopathy: A Case Report and Review of Drug-related Cases in Multiple Myeloma

Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the central nervous system caused by reactivation of John Cunningham (JC) virus. Risk factors for the development of PML include...

Myeloma websites from around the globe

Myeloma UK

Myeloma Australia

Multiple Myeloma Research Foundation

International Myeloma Foundation

Black Swan Research Initiative

Leukaemia & Blood Cancer Foundation NZ

Otago Myeloma Research Unit